Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign and date a consent form agreeing to take part in the study.
• People who are willing to follow all study procedures and are available for the full duration of the trial.
• Men aged 18 years or older.
• People who have been diagnosed with metastatic castration-sensitive prostate cancer (prostate cancer that has spread to other parts of the body and has not yet stopped responding to hormone-lowering treatment), either newly diagnosed or returning after previous surgery or radiation treatment.
• People who are about to start, or have recently started (within the last 14 days), a hormone therapy that lowers testosterone levels (such as leuprolide or degarelix).
• People whose doctor plans to add a second hormone-blocking medication (such as abiraterone, enzalutamide, apalutamide, or darolutamide) to their treatment.
• People whose cancer specialist has given approval to participate in exercise training, taking into account their overall health and any other medical conditions.
• People who are able to swallow tablets or capsules and are willing to follow the medication schedule required by the study.
• People who are able to read, speak, and understand English.

Who may not be able to join:

• People whose prostate cancer has stopped responding to hormone-lowering treatment (known as castration-resistant prostate cancer).
• People whose PSA level has risen after previous surgery or radiation treatment, but whose scans show no signs that the cancer has spread to other parts of the body.
• People who have cancer spread to certain bones (such as the upper thigh bone), a bone affected by the cancer that is at risk of breaking, or another affected area that the treating doctor considers unsafe for walking.
• People who have medical or joint/bone conditions that prevent them from safely using a stationary bike or walking.
• People who have serious heart, kidney, liver, blood, or lung conditions that would prevent safe participation in exercise.
• People who have had unstable chest pain (angina) or a heart attack within the four weeks before starting treatment.
• People who have complex irregular heart rhythms or very severe heart failure symptoms (New York Heart Association class IV).
• People who have severe narrowing of the heart's aortic valve that is causing symptoms.
• People who currently have a blood clot in the lungs (acute pulmonary embolus).
• People who currently have active inflammation of the heart muscle (acute myocarditis).
• People who have a serious eye condition involving abnormal blood vessel growth in the retina that has not been treated.
• People who have recently had bleeding in the retina (the back of the eye).
• People whose blood pressure is not under control (top number above 180 or bottom number above 120).
• People who have severely abnormal levels of minerals in their blood (such as potassium) that the doctor believes could increase the risk of irregular heart rhythms.
• People who have uncontrolled metabolic conditions such as very high blood sugar from diabetes, an overactive thyroid, or severely underactive thyroid.
• People who have symptoms from poor blood flow in their legs or feet (symptomatic peripheral vascular disease).
• People who have previously been treated with taxane- or platinum-based chemotherapy.
• People who have previously been treated with a type of medication called a PARP inhibitor.
• People who have previously been treated with radium-223 or lutetium-177 (types of targeted radiation therapy).

Important: Always verify eligibility with the trial site directly before applying.